News | May 25, 2026
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Nearly one in five women worldwide are now living with obesity
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
But acquisition charges drag earnings into loss
American College of Cardiology and Korean Society of Cardiology convene global experts to address rising cardiometabolic burden
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
In just the last few days, companies including Lupin, Biocon, Alembic Pharmaceuticals and Aurobindo Pharma have announced approvals for 5 mg and 10 mg tablets, all bioequivalent to Farxiga
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
